Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Investor Presentation (October 2026)
29 slides from Legend Biotech's investor presentation, October 2026
Slide 1: Legend Biotech Corporate Presentation
Legend Biotech Corporate Presentation October 2026 © 2025 Legend Biotech. All rights reserved.
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the exchange losses in 2026; the progress of such submissions with the FDA, the EMA and other “Company”) solely for information purpose and does not contain all relevant information regulatory authoriti
Slide 3: Unlocking the Potential of Immune Cells to Treat the Toughest Diseases
Unlocking the Potential of Immune Cells to Treat the Toughest Diseases Positive $657M 14 Profitable1 Operating Cash Flow2 Q2 2026 CARVYKTI Net Trade Sales Pipeline Programs CAR-T Leadership in MM3 Cell Therapy Innovation Durable Global Business • CARVYKTI® is the top-selling CAR-T in a single • Adva
Slide 4: Reaching a Profitability Inflection Point
Reaching a Profitability Inflection Point Strong Underlying Growth Demand, Operating margin improvement from -142% in 2Q 2023 to 15% in 2Q 2026 450 150% Non-GAAP Operating Loss/Income (USD $M) 52% y/y Growth 400 100% 350 50% Operating Margin (%) 300 Revenue ($MM) 250 0% 200 -50% 150 -100% 100 -11 63
Slide 5: Our 2026 Priorities
Our 2026 Priorities Shaping the Next Era of Growth Through Leadership and Innovation 01 02 03 Maximize CARVYKTI® Advancing Our Drive Market Leadership Cell Therapy Profitability Innovation 5
Slide 6: Maximize CARVYKTI Market Leadership
MAXIMIZE CARVYKTI® MARKET LEADERSHIP 6
Slide 7: 10,000+ Patients Have Been Treated with CARVYKTI
10,000+ Patients Have Been Treated with CARVYKTI® “The long-term PFS and OS data with cilta-cel in CARTITUDE 1 and CARTITUDE 4 are unprecedented in BEST IN CLASS STRONG COMMERCIAL relapsed myeloma. When you see MANUFACTURING EXPANSION1 patients achieving durable disease control for years after a sin
Slide 8: Legend and Johnson & Johnson Global Collaboration
Legend and Johnson & Johnson Global Collaboration License Agreement to Develop and Commercialize Cilta-cel with J&J PARTNERSHIP ACCOMPLISHMENTS WORLDWIDE COLLABORATION Enrolled the largest multiple myeloma J&J is the global multiple myeloma market leader CAR-T program to date 50/50% cost-sharing/pro
Slide 9: Earlier Use of CARVYKTI May Increase 5-Year PFS and OS
Earlier Use of CARVYKTI® May Increase 5-Year PFS and OS Based on Latest Data Presented at IMS 2026 Numerically higher PFS and OS at 1-3 prior LOT (CARTITUDE-2 Cohort A) than at ≥3 (CARTITUDE-1) CARTITUDE-2 Cohort A (N=20), 1-3 prior LOT PFS OS 100 5-y PFS 100 5-y OS 1/2 of Patients progression free
Slide 10: Earlier Use of CARVYKTI is Associated With Better Outcomes
Earlier Use of CARYKTI® is Associated With Better Outcomes SAFETY OS by pLOT in CARTITUDE-1 and CARTITUDE-41 • Following implementation of patient management strategies, 100 CARTITUDE-4, 1 pLOT parkinsonism rates were reduced CARTITUDE-4, 2 pLOT from 6% in CARTITUDE-1 75 CARTITUDE-4 and CARTITUDE-1,
Slide 11: Raising the Bar for Progression-Free Survival (PFS)
Raising the Bar for Progression-Free Survival (PFS) CARVYKTI® has demonstrated profound efficacy in patients with RRMM1,2 CARTITUDE-1 CARTITUDE-1 + CARTITUDE-4a CARTITUDE-4a TCE RRMM ≥ 3 pLOT TCE RRMM 3pLOT RRMM 1-3 pLOT N 97 34 176 Median PFS 34.9 months 50.4 months NR (mFUb: 34.0 months) PRESENTED
Slide 12: Significant Market Potential in Earlier Line Multiple Myeloma
Significant Market Potential in Earlier Line Multiple Myeloma 2026 CARVYKTI® MARKET POTENTIAL (US)1: In 20251, • ≤5% of patients were treated with a 5L+Patients Treated BCMA targeting agent (CAR-T, Bi- (2025) Specific, or ADC) in 2L-4L • ≤10% of patients were treated with a 2L-4L Patients CAR-T in 5
Slide 13: Treatment of Myeloma At First Relapse
Treatment of Myeloma At First Relapse Vincent Rajkumar, Professor of Medicine at the Mayo Clinic ASH25 algorithm for Relapsed Myeloma: First Relapse1 Not Refractory to Anti-CD38 Refractory to Anti-CD38 Have access and able to Unable to give cell Have access and able to give cell therapy and Unable t
Slide 14: Driving CARVYKTI Expansion Into the Frontline
Driving CARVYKTI® Expansion Into the Frontline Advancing into earlier lines to broaden use and fuel long-term growth. Active • Global, multi-cohort study (NCT04133636) CARTITUDE-21 • Phase II open-label study of Cilta-cel in various clinical settings Enrollment complete • Global, randomized, registr
Slide 15: Accelerating Growth in the US Through Community & Outpatient Adoption
Accelerating Growth in the United States Through Community & Outpatient Adoption Continued Growing Community Network CARVYKTI® in the Community1 Presence in Community Activation ~70% of RRMM patients 40% are in the community Regional/ Community Hospitals 60% Academic Hospitals Leading BCMA CAR-T sal
Slide 16: CARVYKTI: Unmatched Real World Results in BCMA CAR-T
CARVYKTI®: Unmatched Real World Results in BCMA CAR-T Unrivaled Evidence. Unmatched Experience. mPFS Late Line triple class Data vs. Study Indicated Real-world US Site Data exposed (TCE) Active Key Patient Patients experience Experience Maturity with 3 pLOT Control Characteristics1-4 10,000+ 61.3 •
Slide 17: Optimizing Bridging Therapy
Dhakal B, et al1: USE OF GPRC5D • 134 patients across 18 US academic medical centers and 2 German centers BI-SPECIFIC • 98 RRMM patients received talquetamab bridging therapy and CARVYKTI KEY FINDING There were no cases of IEC colitis or parkinsonism Optimizing Bridging Therapy Is Associated With Im
Slide 18: Updated NCCN Guidelines Recommend Bridging Therapy
Updated NCCN Guidelines Recommend Bridging Therapy National Comprehensive Cancer Network Guidelines Update1 “The panel recommends that talquetamab may be considered as a bridge to BCMA CAR-T Therapy in RRMM…” Updated January 2026 1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guid
Slide 19: The Proven Leader Forging the Path to Cure
The Proven Leader Forging the Path to Cure Highly Well Earlier Treatment One-Time Effective Tolerated is Better Treatment • First and only CAR-T • Parkinsonism has • Efficacy, safety, and • One-time infusion with demonstrated decreased in earlier manufacturing provides freedom to Overall Survival be
Slide 20: Advancing Our Cell Therapy Innovation
ADVANCING OUR CELL THERAPY INNOVATION 20
Slide 21: Advancing a Robust, Differentiated Cell Therapy Pipeline
Advancing a Robust, Differentiated Cell Therapy Pipeline Program Target Indication Pre-Clinical Phase I Phase II Phase III NDA Current Status Partner CARVYKTI®: BCMA-directed Autologous Therapy NDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)(1) Multi-Regional Clinical Trial Patient follow-
Slide 22: Advancing R&D Innovation to Drive Long-Term Growth
Advancing R&D Innovation to Drive Long-Term Growth Lean Approach to Clinical Proof of Concept Utilizes R&D Investments Efficiently Unique Proof-of-Concept Model Accelerates Global Entry • Leverages investigator-initiated trials (IITs) in China to rapidly establish early 1 clinical proof-of-concept •
Slide 23: Leveraging Stand-Alone Cell Therapy Leadership In Vivo
Leveraging Stand-Alone Cell Therapy Leadership In Vivo TaVec (T-Cell Activation Vector) Design and Mechanism of Action TARGET MECHANISM • Oncology and • TaVec platform autoimmune indications • Provide T cell specificity, activation and safety • Mutations in glycoprotein and CD3 single-chain variable
Slide 24: Promising Data in LB2501: In Vivo CD19/CD20 CAR-T for NHL
Promising Data in LB2501: In Vivo CD19/CD20 CAR-T for NHL Percent Change from Baseline (DL2) RESULTS PRESENTED AT EHA1 2026 20 • Dose Level 2 (DL2) across DLBCL2, Change in target lesions 0 from baseline (%) -20 MCL3 and FL4: -40 • 100% (6/6) ORR5 -60 CR • 83.3% (5/6) CR6 CR -80 CR CR CR PR • The me
Slide 25: 2026 Commitment to Business Development
2026 Commitment to Business Development Generate Non-Dilutive Funding Through Strategic Partnerships Maintain Hematology Leadership Continue Innovation Through Enabling Technologies Generate Other Revenue Beyond CARVYKTI® Build on Core Cell & Gene Therapies & Expand Beyond 25
Slide 26: Drive Profitability
6LEGEND Bol G@areEcu DRIVE PROFITABILITY
Slide 27: Strong Balance Sheet Fueled by CARVYKTI Growth
Strong Balance Sheet Fueled by CARVYKTI Growth CARVYKTI® Net Trade Sales ($MM) $657M 50% 700 Net Sales (Q2 2026) YoY Growth (Q2 2025) 185 600 ~$965M 74% 164 500 128 135 472 Cash, cash equivalents, Compound Annual 81 400 420 433 & time deposits as of Growth Rate (CAGR) 396 300 31 51 358 June 2026 sin
Slide 28: 2026 Priorities to Unlock Next Stage of Growth
2026 Priorities to Unlock Next Stage of Growth PRIORITIES GOALS TIMING • Deliver sequential CARVYKTI growth ONGOING Maximize CARVYKTI® • 3/4 of CARVYKTI® orders from 2-4L ONGOING Market Leadership • Present additional long-term data ONGOING • Continued globalization ONGOING Advancing Our • Present i
Slide 29: Thank You
Thank You
Legend Biotech — Investor Presentation (October 2026) on 6ix